LEADER 01262nam a2200265 i 4500 001 991001179559707536 005 20020502184722.0 008 970401s1988 it ||| | ita 020 $a8813165056 035 $ab11475146-39ule_inst 035 $aPRUMB56289$9ExL 040 $aScuola per assistenti sociali$bita 082 0 $a346.03 100 1 $aVisintini, Giovanna$0437375 245 13$aLa giurisprudenza per massime e il valore del precedente :$bcon particolare riguardo alla responsabilità civile :$batti del Convegno promosso dall'Istituo di diritto privato della Facoltà di giurisprudenza in collaborazione con la rivista Contratto e impresa :$bGenova, 11 e 12 marzo 1988 /$ca cura di Giovanna Visintini 260 $aPadova :$bCEDAM,$c1988 300 $aX, 504 p. ;$c24 cm. 440 3$aLe monografie di Contratto e impresa ;$v7 650 4$aResponsabilità civile$xCongressi - Genova$y1988 907 $a.b11475146$b02-04-14$c01-07-02 912 $a991001179559707536 945 $aLE024 DIR PB C VI 9$g1$iLE024N-3802$lle021$nex DUSS$o-$pE0.00$q-$rl$s- $t0$u0$v0$w0$x0$y.i11665014$z01-07-02 996 $aGiurisprudenza per massime e il valore del precedente$9811746 997 $aUNISALENTO 998 $ale021$b01-01-97$cm$da $e-$fita$git $h3$i1 LEADER 04503nam 22007335 450 001 9910847083403321 005 20251113155231.0 010 $a3-031-52864-6 024 7 $a10.1007/978-3-031-52864-4 035 $a(CKB)31253135600041 035 $a(MiAaPQ)EBC31266962 035 $a(Au-PeEL)EBL31266962 035 $a(MiAaPQ)EBC31233397 035 $a(Au-PeEL)EBL31233397 035 $a(DE-He213)978-3-031-52864-4 035 $a(EXLCZ)9931253135600041 100 $a20240329d2024 u| 0 101 0 $aeng 135 $aur||||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aDrug Delivery and Targeting /$fedited by Monika Schäfer-Korting, Ulrich S. Schubert 205 $a1st ed. 2024. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2024. 215 $a1 online resource (408 pages) 225 1 $aHandbook of Experimental Pharmacology,$x1865-0325 ;$v284 311 08$a3-031-52863-8 320 $aIncludes bibliographical references. 327 $aPart I. Nanoparticles and other Advanced Technologies -- Knowledge-based design of multi-functional polymer-based nanoparticles -- Stimuli-responsive non-viral nanoparticles for gene delivery -- Sustainability in drug and nano-particle processing -- Advanced formulation approaches for proteins -- Microneedles and polymer films ? delivery of peptides, proteins and nucleic acids -- Advances in vaccine delivery enhancers ? small molecules and nanomaterials -- Biodegradable long acting injectables: Platform technology and industrial challenges -- Part II. Visualization Technologies -- Visualization of Nano-carriers and Drugs in Cells and Tissue -- Characterization of drug delivery systems by transmission electron microscopy -- Part III. Target Specific Delivery -- Blood-brain barrier-crossing strategies for improved treatment of CNS disorders -- Interactions of nano-systems with immune cells and cancer cells ? a roadmap to clinical use?- Progress in ocular drug delivery: challenges and constraints -- New therapeutic options in pulmonal diseases ? sphingolipids and sphingolipid metabolism -- Molecular therapeutics for pulmonary diseases ? the need for drug targeting -- Delivery of mitochondrial RNA -- Part IV. Concerted Actions ? Thinking the Drug from the Beginning -- ATMP formulations and delivery -- Preclinical testing and approval of ATMP -- Looking to the future ? drug delivery in the prophylaxis and therapy of severe and chronic diseases. 330 $aSince the publication of the Handbook of Experimental Pharmacology Vol. 197 in 2010 there have been important advances in drug development, drug delivery and ? more recently ? drug targeting. This is in particular relevant with the new generation of drugs acting on the immune system and tumors. These are quite often accompanied by major adverse reactions. Safe therapy is, therefore, an important area of research, in particular in chronic diseases and in persons of old age. In addition, the Covid-19 pandemic has brought renewed attention to vaccinations against viral infections, and mRNA vaccines have been tested for vaccination in tumor therapy, too. Vaccine delivery has stimulated important research on carriers which may pave the way for other applications and enhance a path to e.g. CRISPR-cas therapy. 410 0$aHandbook of Experimental Pharmacology,$x1865-0325 ;$v284 606 $aPharmacy 606 $aPharmacology 606 $aMedicine$xResearch 606 $aBiology$xResearch 606 $aClinical medicine$xResearch 606 $aPharmacovigilance 606 $aPharmacy 606 $aPharmacology 606 $aTranslational Research 606 $aClinical Research 606 $aDrug Safety and Pharmacovigilance 615 0$aPharmacy. 615 0$aPharmacology. 615 0$aMedicine$xResearch. 615 0$aBiology$xResearch. 615 0$aClinical medicine$xResearch. 615 0$aPharmacovigilance. 615 14$aPharmacy. 615 24$aPharmacology. 615 24$aTranslational Research. 615 24$aClinical Research. 615 24$aDrug Safety and Pharmacovigilance. 676 $a615.6 702 $aScha?fer-Korting$b Monika 702 $aSchubert$b U$g(Ulrich), 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910847083403321 996 $aDrug delivery and targeting$9982230 997 $aUNINA